{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:41:39Z","timestamp":1792233699831,"version":"4.4.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Outpatients aged 7\u201317 years meeting\n                      <jats:italic toggle=\"yes\">Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                      , 4th edition, diagnostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of three dosing arms. In Arm I, participants began treatment at a dose of 300\u2009mg of lithium twice daily. The starting dose of lithium in Arms II and III was 300\u2009mg thrice daily. Patients in Arms I and II could have their dose increased by 300\u2009mg\/day, depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they could also have their dose of lithium increased by 300\u2009mg per day. Youths weighing &lt;30\u2009kg were automatically assigned to Arm I, whereas youths weighing \u226530\u2009kg were randomly assigned to Arm I, II, or III. Randomization was balanced by age (7\u201311 years, 12\u201317 years) and sex in approximately equal numbers.\n                      <jats:italic toggle=\"yes\">A priori<\/jats:italic>\n                      response criteria were defined as a Clinical Global Impressions-Improvement scale score of \u22642 and a 50% decrease from baseline on the Young Mania Rating Scale.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 61 youths [32 males (52.5%)] who received open-label lithium, 60 youths completed at least 1 week of treatment and returned for a postbaseline assessment. Most patients had a \u226550% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300\u2009mg thrice daily (with an additional 300\u2009mg increase during the first week), followed by 300\u2009mg weekly increases until\n                      <jats:italic toggle=\"yes\">a priori<\/jats:italic>\n                      stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2010.0084","type":"journal-article","created":{"date-parts":[[2011,6,10]],"date-time":"2011-06-10T15:10:35Z","timestamp":1307718635000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":54,"title":["Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder"],"prefix":"10.1177","volume":"21","author":[{"given":"Robert L.","family":"Findling","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Kafantaris","sequence":"additional","affiliation":[{"name":"The Feinstein Institute for Medical Research of the North Shore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Pavuluri","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora K.","family":"McNamara","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"McClellan","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Frazier","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmarie","family":"Sikich","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kowatch","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqui","family":"Lingler","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Faber","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieana M.","family":"Rowles","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[{"name":"The EMMES Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perdita","family":"Taylor-Zapata","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,6,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f94ad0"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198001000-00009"},{"key":"e_1_3_3_4_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th(DSM-IV)Washington, DC: American Psychiatric Association, 1994.","edition":"4"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2004.08.003"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.2.175"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360044034"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/106342669700500404"},{"key":"e_1_3_3_9_1","first-page":"518","article-title":"Lithium salts in the treatment of psychotic excitement","volume":"78","author":"Cade JF","year":"1949","unstructured":"Cade JF. Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ, 78:518\u2013520. 2000.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_10_1","volume-title":"ADHD Rating Scale - IV: Checklists, Norms, and Clinical Interpretation","author":"DuPaul GJ","year":"1998","unstructured":"DuPaul GJ, , Power TJ, , Anastopoulos AD, , Reid R. ADHD Rating Scale - IV: Checklists, Norms, and Clinical Interpretation. New York: The Guilford Press, 1998."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-2-21"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2001.30405.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181e66a62"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000046893.27264.53"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05164yel"},{"key":"e_1_3_3_16_1","first-page":"43","volume-title":"Treatment of Bipolar Disorder in Children and Adolescents","author":"Findling RL","year":"2008","unstructured":"Findling RL, , Pavuluri MN, , Lithium. Treatment of Bipolar Disorder in Children and Adolescents. Geller B, , DelBello M. New York: Guilford Press, 2008; 43\u201368."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.5.459"},{"issue":"10","key":"e_1_3_3_18_1","first-page":"5","article-title":"Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment","volume":"63","author":"Goodwin FK","year":"2002","unstructured":"Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry, 63,Suppl 10:5\u201312. 2002.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200402000-00018"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00750.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199801000-00018"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750143500"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198726060-00015"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CHI.0000070247.24125.24"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_3_3_26_1","first-page":"501","volume-title":"Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines","author":"Klein RG","year":"1994","unstructured":"Klein RG, , Abikoff H, , Barkley RA, , Campbell M, , Leckman JF, , Ryan ND, , Solanto MV, , Whalen CK. Clinical trials in children, adolescents. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Prien RF, , Robinson DS. New York: Raven Press, Ltd., 1994; 501\u2013546."},{"key":"e_1_3_3_27_1","volume-title":"Presented at 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry","author":"Kowatch RA","unstructured":"Kowatch RA, , Findling RL, , Scheffer RE, , Stanford K. Pediatric bipolar collaborative mood stabilizer trial. Presented at 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 23\u201328, 2007, Boston, MA."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200503000-00006"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000242240.69678.c4"},{"key":"e_1_3_3_30_1","volume-title":"Family Environment Scale Manual","author":"Moos R","year":"1984","unstructured":"Moos R, , Moos E. Family Environment Scale Manual. Palo Alto, CA: Consulting Psychologist Press, 1984."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.2005.01649.x"},{"key":"e_1_3_3_32_1","first-page":"839","article-title":"Clinical global impressions scale","volume":"21","author":"[NIMH] National Institute of Mental Health:","year":"1985","unstructured":"[NIMH] National Institute of Mental Health:. Clinical global impressions scale. Psychopharmacol Bull, 21:839\u2013843. 1985.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000205700.40700.50"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.05.017"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020678"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00011"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_3_38_1","first-page":"1","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson GM","year":"1970","unstructured":"Simpson GM, , Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl, 212:1\u201319. 1970.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.132.2.164"},{"key":"e_1_3_3_40_1","first-page":"65","article-title":"The drug use screening inventory: Its applications in the evaluation and treatment of alcohol and other drug abuse","volume":"15","author":"Tarter RE","year":"1991","unstructured":"Tarter RE, , Hegedus AM. The drug use screening inventory: Its applications in the evaluation and treatment of alcohol and other drug abuse. Alcohol Health Res World, 15:65\u201375. 1991.","journal-title":"Alcohol Health Res World"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.clinpsy.2.022305.095301"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00006"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111932"},{"key":"e_1_3_3_44_1","unstructured":"United States Food and Drug Administration (FDA). www.fda.gov\/medwatch\/SAFETY\/2003\/03Jan_labels\/Lithium%20PI.pdf 2003."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198810000-00009"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)60603-8"},{"key":"e_1_3_3_47_1","volume-title":"Wechsler Abbreviated Scale of Intelligence Manual","author":"Wechsler DA","year":"1999","unstructured":"Wechsler DA. Wechsler Abbreviated Scale of Intelligence Manual. San Antonio, TX: The Psychological Corporation, 1999."},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0517"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2010.0084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2010.0084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:01Z","timestamp":1777388101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2010.0084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1089\/cap.2010.0084"],"URL":"https:\/\/doi.org\/10.1089\/cap.2010.0084","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}